HALOZYME THERAPEUTICS, INC. OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax
HALOZYME THERAPEUTICS, INC. (HALO) reported OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax of $93.00 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-28.
Discontinued › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax · last filed 2017-02-28
- HALOZYME THERAPEUTICS, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2016 was $93.00K.
- HALOZYME THERAPEUTICS, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2015 was -$58.00K.
- HALOZYME THERAPEUTICS, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2014 was -$58.00K, a 441.18% decline from fiscal 2013.
- HALOZYME THERAPEUTICS, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2013 was $17.00K.
| Period end | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 12 month |
|---|---|
| 2016-12-31 | $93.00K 10-K · filed 2017-02-28 |
| 2015-12-31 | -$58.00K 10-K · filed 2017-02-28 |
| 2014-12-31 | -$58.00K 10-K · filed 2017-02-28 |
| 2013-12-31 | $17.00K 10-K · filed 2016-02-29 |
| 2012-12-31 | $0.00 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |